Avacopan in the treatment of ANCA-associated vasculitis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376126" target="_blank" >RIV/00216208:11110/18:10376126 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/18:10376126

Result on the web

<a href="https://doi.org/10.1080/13543784.2018.1472234" target="_blank" >https://doi.org/10.1080/13543784.2018.1472234</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/13543784.2018.1472234" target="_blank" >10.1080/13543784.2018.1472234</a>

Result language

angličtina

Original language name

Avacopan in the treatment of ANCA-associated vasculitis

Original language description

Introduction: ANCA-associated vasculitis (AAV) is a rare but potentially life-threatening disease. Currently used induction treatment (cyclophosphamide or rituximab with high-dose corticosteroids) has significantly improved outcome of AAV, but is associated with high toxicity. Alternative complement pathway activation was shown to play a role in the pathogenesis of AAV, thus providing rationale for the use of avacopan, a selective inhibitor of C5a receptor, in the treatment of AAV.Areas covered: Pharmacokinetic and pharmocodynamic properties of avacopan, clinical efficacy and safety and tolerability of avacopan in so far performed clinical trials in patients with AAV are reviewed and discussed.Expert opinion: Avacopan was shown to have at least similar efficacy compared to high dose corticosteroids in patients with active AAV with renal involvement, while there were no major safety issues reported. Replacement of corticosteroids should decrease the corticosteroid-related toxicity and improve long-term outcome of patients with AAV even though this still needs to be confirmed in a larger trial. Data on long-term outcome of avacopan-treated patients are currently lacking and will be eagerly awaited. In the future, avacopan could replace corticosteroids not only in the induction phase, but also in the maintenance treatment of AAV.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Expert Opinion on Investigational Drugs

ISSN

1354-3784

e-ISSN

—

Volume of the periodical

27

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

491-496

UT code for WoS article

000432689500006

EID of the result in the Scopus database

2-s2.0-85046675551